Genelux CorporationGNLXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank50
3Y CAGR-53.1%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-53.1%/yr
Annual compound
Percentile
P50
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 4.49% |
| 2024 | 48.81% |
| 2023 | 40.64% |
| 2022 | 43.66% |
| 2021 | 1.48% |
| 2020 | -17.33% |
| 2019 | 0.00% |